Li Chia-Ling, Lin Hsiao-Chuan, Lin Chien-Yu, Hsu Teh-Fu
Department of Nursing, Hsinchu MacKay Memorial Hospital, Hsinchu 30071, Taiwan.
School of Nursing, National Yang-Ming University, Taipei 11221, Taiwan.
J Clin Med. 2019 Jan 9;8(1):64. doi: 10.3390/jcm8010064.
We aimed to explore the efficacy of hypertonic saline nasal irritation (HSNI) for improving nasal symptoms and quality of life, and for decreasing oral antihistamine consumption in children with allergic rhinitis (AR). We conducted a systematic search of PubMed, Medline, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Chinese Electronic Periodicals Service, and Cochrane Library of Controlled Trials databases for prospective randomized, controlled trials assessing HSNI effects in children with AR and published before December 2017. Two authors independently assessed each trial's quality and extracted data for a meta-analysis. We included four trails comprising 351 patients. HSNI improved patients' nasal symptom scores (mean difference 1.82 points after treatment; 95% confidence interval (CI), 0.35⁻3.30; ² = 64%; = 0.02) and a significantly lower rescue antihistamine use rate (risk ratio (RR), 0.68; 95% CI, 0.48⁻0.95; ² = 28%; = 0.02). Analyses comparing HSNI with isotonic saline nasal irrigation (ISNI) showed better nasal symptom scores (mean difference, 1.22 points; 95% CI, 1.01⁻1.44; ² = 0%; < 0.001) in patients in the HSNI group, although the antihistamine use (RR, 0.84; 95% CI, 0.64⁻1.10; ² = 0%; = 0.2) and adverse effect rates were similar between groups. Compared with ISNI, HSNI may be a reasonable adjunctive treatment for children with AR.
我们旨在探讨高渗盐水鼻腔刺激(HSNI)对改善变应性鼻炎(AR)患儿鼻腔症状、生活质量以及减少口服抗组胺药用量的疗效。我们对PubMed、Medline、护理学与健康相关文献累积索引、EMBASE、中国知网以及Cochrane对照试验图书馆数据库进行了系统检索,以查找2017年12月之前发表的评估HSNI对AR患儿疗效的前瞻性随机对照试验。两位作者独立评估每个试验的质量,并提取数据进行荟萃分析。我们纳入了4项试验,共351例患者。HSNI改善了患者的鼻腔症状评分(治疗后平均差值为1.82分;95%置信区间(CI)为0.35至3.30;I² = 64%;P = 0.02),且急救抗组胺药使用率显著降低(风险比(RR)为0.68;95%CI为0.48至0.95;I² = 28%;P = 0.02)。将HSNI与等渗盐水鼻腔冲洗(ISNI)进行比较的分析显示,HSNI组患者的鼻腔症状评分更好(平均差值为1.22分;95%CI为1.01至1.44;I² = 0%;P < 0.001),尽管两组之间抗组胺药使用情况(RR为0.84;95%CI为0.64至1.10;I² = 0%;P = 0.2)和不良反应发生率相似。与ISNI相比,HSNI可能是AR患儿一种合理的辅助治疗方法。